NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free ENFN Stock Alerts $9.67 +0.03 (+0.31%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$9.53▼$9.7050-Day Range$8.30▼$9.7752-Week Range$7.52▼$11.56Volume301,288 shsAverage Volume338,992 shsMarket Capitalization$1.24 billionP/E Ratio322.44Dividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enfusion alerts: Email Address Enfusion MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside3.5% Downside$9.33 Price TargetShort InterestBearish4.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 5 Articles This WeekInsider TradingSelling Shares$1,179 Sold Last QuarterProj. Earnings Growth142.86%From $0.07 to $0.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.86 out of 5 starsComputer And Technology Sector540th out of 598 stocksPrepackaged Software Industry183rd out of 200 stocks 0.8 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageEnfusion has only been the subject of 3 research reports in the past 90 days.Read more about Enfusion's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.73% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Enfusion has recently increased by 2.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 1.7 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enfusion this week, compared to 2 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,179.00 in company stock.Percentage Held by Insiders39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enfusion's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 142.86% in the coming year, from $0.07 to $0.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 322.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 136.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 322.44, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 239.94.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.82. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 14.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enfusion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyI’m afraid WWIII is a very real possibility As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film.Take a look. About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesMay 14, 2024 | americanbankingnews.comEnfusion (NYSE:ENFN) Research Coverage Started at Morgan StanleyMay 13, 2024 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q1 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q1 2024 Earnings Call TranscriptMay 11, 2024 | finance.yahoo.comEnfusion First Quarter 2024 Earnings: EPS Misses ExpectationsMay 9, 2024 | msn.comENFN Stock Earnings: Enfusion Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comEnfusion Announces First Quarter 2024 ResultsMay 7, 2024 | finance.yahoo.comHas Enfusion, Inc.'s (NYSE:ENFN) Impressive Stock Performance Got Anything to Do With Its Fundamentals?April 18, 2024 | businesswire.comEnfusion Announces Date of First Quarter 2024 ResultsApril 17, 2024 | morningstar.comEnfusion Inc Class AApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNApril 4, 2024 | msn.comThe 3 Most Undervalued Under-$10 Stocks to Buy in April 2024April 2, 2024 | finance.yahoo.comWill Enfusion (ENFN) Grow Revenue And Expand Margins In The Future?April 2, 2024 | businesswire.comConnexPay Appoints Ben Peters as Chief Executive OfficerMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 22, 2024 | markets.businessinsider.comEnfusion’s Growth Strategy Met with Sell Rating Amid Market and Strategic ChallengesMarch 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Technology Stocks: GoDaddy (GDDY) and Enfusion (ENFN)March 20, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 15, 2024 | markets.businessinsider.comWall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024March 14, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Copperleaf Tech (OtherCPLFF), Rackspace Technology (RXT) and Enfusion (ENFN)March 12, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Enfusion (ENFN)March 12, 2024 | msn.comEnfusion reports mixed Q4 results; initiates FY24 outlookSee More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside-3.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio322.44 Forward P/E Ratio138.14 P/E Growth2.82Net Income$6.03 million Net Margins1.40% Pretax Margin3.04% Return on Equity6.60% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio3.44 Sales & Book Value Annual Sales$174.54 million Price / Sales7.10 Cash Flow$0.15 per share Price / Cash Flow65.43 Book Value$0.65 per share Price / Book14.88Miscellaneous Outstanding Shares128,070,000Free Float77,892,000Market Cap$1.24 billion OptionableOptionable Beta0.97 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 53)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 51)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMs. Valeria Gutowski (Age 42)Chief Accounting Officer Mr. Daniel Groman (Age 35)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMr. Joseph DefeoGlobal Head of Managed Services ProductionMr. Jeff YoungHead of ImplementationMr. Robert TaylorHead of Client SupportMore ExecutivesKey CompetitorsDoceboNASDAQ:DCBOOperaNASDAQ:OPRAFastlyNYSE:FSLYPDF SolutionsNASDAQ:PDFSCouchbaseNASDAQ:BASEView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCSold 19,303 shares on 5/16/2024Ownership: 1.262%California State Teachers Retirement SystemBought 3,556 shares on 5/16/2024Ownership: 0.028%Brown Capital Management LLCSold 1,842,060 shares on 5/15/2024Ownership: 7.789%Quadrature Capital LtdBought 11,826 shares on 5/15/2024Ownership: 0.009%Price T Rowe Associates Inc. MDBought 11,013 shares on 5/15/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ENFN shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price target for 2024? 6 Wall Street analysts have issued 1 year price objectives for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's share price to reach $9.33 in the next twelve months. This suggests that the stock has a possible downside of 3.5%. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2024? Enfusion's stock was trading at $9.70 on January 1st, 2024. Since then, ENFN shares have decreased by 0.3% and is now trading at $9.67. View the best growth stocks for 2024 here. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ENFN earnings forecast. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.05. The business earned $48.05 million during the quarter, compared to the consensus estimate of $47.67 million. Enfusion had a net margin of 1.40% and a trailing twelve-month return on equity of 6.60%. During the same period in the previous year, the firm earned $0.04 earnings per share. What guidance has Enfusion issued on next quarter's earnings? Enfusion issued an update on its FY 2024 earnings guidance on Tuesday, May, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $205.6 million. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (7.79%), Vanguard Group Inc. (2.85%), Janus Henderson Group PLC (1.26%), Wasatch Advisors LP (0.62%), Swiss National Bank (0.05%) and Principal Financial Group Inc. (0.04%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
